查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679416

轉移性肺腺癌治療市場規模、佔有率、趨勢分析報告：按治療、最終用途、地區和細分市場預測，2025-2030 年

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

轉移性肺腺癌治療市場的成長和趨勢

根據 Grand View Research, Inc. 的新報告，全球轉移性肺腺癌治療市場規模預計到 2030 年將達到 92.9 億美元，2025 年至 2030 年的複合年成長率為 11.3%。

這種擴張背後有幾個關鍵因素，包括盛行率的增加、治療技術的進步以及監管和政府的支持措施。根據世界衛生組織 (WHO) 的數據，肺癌仍然是全球最常見的癌症，每年約有 250 萬新病例，佔所有新癌症病例的 12.4%。如此高的發生率凸顯了對有效治療方法的迫切需求。

治療領域的最新趨勢對市場發展貢獻巨大。包括 ALK 抑制劑和 EGFR 抑制劑在內的標靶治療等創新徹底改變了轉移性肺腺癌的治療。例如，2024年3月，輝瑞發布了第3階段CROWN試驗的長期追蹤資料。該研究評估了第三代 ALK 抑制劑 LORBRENA 與 XALKORI 對新診斷的 ALK 陽性晚期非小細胞肺癌 (NSCLC) 患者的療效。 Lorbrena（勞拉替尼）和Tagrisso（Osimertinib）等藥物為患者帶來了新的希望，提高了存活率和生活品質。此外，查核點抑制劑等免疫療法日益普及的情況也進一步擴大了治療選擇。

監管機構在促進市場成長方面發揮著至關重要的作用。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等機構已經對有前景的治療方法實施了快速核准流程，加速了患者獲得新治療方法的機會。此外，美國的國家癌症登月計劃和歐盟的「地平線歐洲」計劃等政府舉措正在提供研究資金並支持新治療方法的開發，從而有助於擴大市場並開發轉移性肺腺癌的治療方案。

轉移性肺腺癌治療市場報告重點

  • 根據治療方法，市場分為化療、標靶治療、免疫治療、放射線治療和其他治療。 2024年，化療部分在轉移性肺腺癌治療市場中佔最大收益佔有率，為36%。
  • 2024 年，醫院部門將佔據最大的收益佔有率，達到 63.9%。醫院通常擁有先進的診斷和治療設施，是進行複雜癌症治療的合適環境。
  • 北美轉移性肺腺癌治療市場受到高疾病盛行率和對技術創新的重視的驅動。肺癌，尤其是腺癌的盛行率不斷上升，導致人們採用針對腫瘤基因特徵的更個人化的治療策略。
  • 由於能夠精準針對癌症的特定分子促進因素，標靶治療領域預計將成為成長最快的領域，從 2025 年到 2030 年的複合年成長率為 12.9%。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 轉移性肺腺癌治療市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析

第4章轉移性肺腺癌治療市場：治療業務分析

  • 2024年和2030年的治療市場佔有率
  • 治療細分儀表板
  • 2018 年至 2030 年各治療領域的市場規模、預測與趨勢分析
  • 化療
  • 標靶治療
  • 免疫療法
  • 放射治療
  • 其他

5. 轉移性肺腺癌治療市場-最終用途業務分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 最終用途細分儀表板
  • 2018 年至 2030 年按最終用途分類的市場規模、預測和趨勢分析
  • 醫院
  • 專科診所
  • 其他

第6章轉移性肺腺癌治療市場：按地區估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Pfizer Inc.
    • Eli Lilly and Company
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Merck KGaA（EMD Serono）
    • F. Hoffmann-La Roche Ltd
    • GSK plc.
    • AbbVie Inc.
Product Code: GVR-4-68040-431-1

Metastatic Lung Adenocarcinoma Treatment Market Growth & Trends:

The global metastatic lung adenocarcinoma treatment market size is estimated to reach USD 9.29 billion by 2030, expanding at a CAGR of 11.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This expansion is fueled by several key factors, including the rising prevalence of the disease, advancements in treatment technologies, and supportive regulatory and government initiatives. According to the World Health Organization (WHO), lung cancer remains the most diagnosed cancer globally, with approximately 2.5 million new cases each year, representing 12.4% of all new cancer cases. This high incidence rate underscores the urgent demand for effective treatment solutions.

Recent developments in treatment have significantly contributed to market growth. Innovations such as targeted therapies, including ALK inhibitors and EGFR inhibitors, have revolutionized the management of metastatic lung adenocarcinoma. For instance, in March 2024, Pfizer Inc. published long-term follow-up data from the Phase 3 CROWN trial. This study assessed the effectiveness of LORBRENA, a third-generation ALK inhibitor, in comparison to XALKORI for patients with newly diagnosed, ALK-positive advanced non-small cell lung cancer (NSCLC). Drugs such as LORBRENA (lorlatinib) and TAGRISSO (osimertinib) offer new hope for patients, leading to improved survival rates and quality of life. Moreover, the increasing adoption of immunotherapies, such as checkpoint inhibitors, has further expanded treatment options.

Regulatory bodies play a crucial role in facilitating market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval processes for promising therapies, accelerating patient access to new treatments. Additionally, government initiatives, such as the National Cancer Moonshot Initiative in the U.S. and the European Union's Horizon Europe program, are funding research and supporting the development of novel therapies, contributing to the market's expansion and the advancement of treatment options for metastatic lung adenocarcinoma.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

  • Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. In 2024, the chemotherapy segment accounted for the largest revenue share of 36% in metastatic lung adenocarcinoma treatment market
  • The hospital segment accounts for the largest revenue share of 63.9% in 2024. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care
  • The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors
  • The targeted therapy segment is anticipated to emerge as the fastest-growing segment and register a CAGR of 12.9% from 2025 to 2030, owing to its ability to target specific molecular drivers of cancer precisely.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Metastatic Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Metastatic Lung Adenocarcinoma Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Treatment, 2018 to 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Metastatic Lung Adenocarcinoma Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Metastatic Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamic
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamic
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamic
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamic
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamic
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamic
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key Country Dynamic
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Spain Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Italy
      • 6.5.6.1. Key Country Dynamic
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Italy Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamic
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamic
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Norway Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamic
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamic
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamic
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamic
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamic
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamic
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamic
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamic
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamic
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamic
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamic
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamic
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamic
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Eli Lilly and Company
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. AstraZeneca
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Bristol-Myers Squibb Company
      • 7.5.4.1. Participant's overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Boehringer Ingelheim International GmbH
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Novartis AG
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Merck KGaA (EMD Serono)
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. F. Hoffmann-La Roche Ltd
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. GSK plc.
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. AbbVie Inc.
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 4. Global Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 5. Global Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 6. North America Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 7. North America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8. North America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9. U.S. Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10. U.S. Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 11. Canada Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12. Canada Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 13. Mexico Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 14. Mexico Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15. Europe Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 16. Europe Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17. Europe Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18. UK Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19. UK Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 20. Germany Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21. Germany Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 22. France Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23. France Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 24. Spain Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25. Spain Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 26. Italy Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27. Italy Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28. Denmark Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29. Denmark Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 30. Sweden Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31. Sweden Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 32. Norway Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 33. Norway Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37. China Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38. China Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 39. Japan Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40. Japan Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 41. India Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42. India Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43. South Korea Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44. South Korea Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 45. Australia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 46. Australia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 47. Thailand Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 48. Thailand Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 49. Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 50. Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51. Latin America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 52. Brazil Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53. Brazil Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 54. Argentina Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 55. Argentina Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59. South Africa Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60. South Africa Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 63. UAE Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 64. UAE Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65. Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 66. Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Metastatic Lung Adenocarcinoma Treatment Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Treatment and End Use Outlook (USD Million)
  • Fig. 10 Competitive Landscape
  • Fig. 11 Metastatic Lung Adenocarcinoma Treatment Market Dynamics
  • Fig. 12 Metastatic Lung Adenocarcinoma Treatment Market: Porter's Five Forces Analysis
  • Fig. 13 Metastatic Lung Adenocarcinoma Treatment Market: PESTLE Analysis
  • Fig. 14 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Segment Dashboard
  • Fig. 15 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Market Share Analysis, 2024 & 2030
  • Fig. 16 Chemotherapy Market, 2018 - 2030 (USD Million)
  • Fig. 17 Targeted Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy Market, 2018 - 2030 (USD Million)
  • Fig. 19 Radiation Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 20 Others Market, 2018 - 2030 (USD Million)
  • Fig. 21 Metastatic Lung Adenocarcinoma Treatment Market: End Use Segment Dashboard
  • Fig. 22 Metastatic Lung Adenocarcinoma Treatment Market: End Use Market Share Analysis, 2024 & 2030
  • Fig. 23 Hospitals Market, 2018 - 2030 (USD Million)
  • Fig. 24 Specialty Clinics Market, 2018 - 2030 (USD Million)
  • Fig. 25 Others Market, 2018 - 2030 (USD Million)
  • Fig. 26 Metastatic Lung Adenocarcinoma Treatment Market Revenue, By Region
  • Fig. 27 Regional Marketplace: Key Takeaways
  • Fig. 28 Regional Marketplace: Key Takeaways
  • Fig. 29 North America Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Country Dynamics
  • Fig. 31 U.S. Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Country Dynamics
  • Fig. 33 Canada Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico Country Dynamics
  • Fig. 35 Mexico Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 37 UK Country Dynamics
  • Fig. 38 UK Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Country Dynamics
  • Fig. 40 Germany Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 41 France Country Dynamics
  • Fig. 42 France Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Country Dynamics
  • Fig. 44 Spain Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 45 Italy Country Dynamics
  • Fig. 46 Italy Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark Country Dynamics
  • Fig. 48 Denmark Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden Country Dynamics
  • Fig. 50 Sweden Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 51 Norway Country Dynamics
  • Fig. 52 Norway Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 54 Japan Country Dynamics
  • Fig. 55 Japan Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 56 China Country Dynamics
  • Fig. 57 China Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 58 India Country Dynamics
  • Fig. 59 India Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea Country Dynamics
  • Fig. 61 South Korea Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia Country Dynamics
  • Fig. 63 Australia Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 64 Thailand Country Dynamics
  • Fig. 65 Thailand Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil Country Dynamics
  • Fig. 68 Brazil Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina Country Dynamics
  • Fig. 70 Argentina Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 71 Middle East & Africa Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa Country Dynamics
  • Fig. 73 South Africa Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 74 Saudi Arabia Country Dynamics
  • Fig. 75 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 76 UAE Country Dynamics
  • Fig. 77 UAE Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 78 Kuwait Key Country Dynamics
  • Fig. 79 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 80 Company Categorization
  • Fig. 81 Company Market Position Analysis
  • Fig. 82 Strategic Framework